Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-10 5:23 pm Purchase |
2025-04-03 | 13G | Karyopharm Therapeutics Inc. KPTI |
Affinity Healthcare Fund, LP | 664,224 7.830% |
664,224 (New Position) |
Filing History |
| 2024-12-31 4:13 pm Purchase |
2024-12-23 | 13G | Avalo Therapeutics, Inc. AVTX |
Affinity Healthcare Fund, LP | 550,765 5.300% |
550,765 (New Position) |
Filing History |
| 2024-12-09 4:14 pm Purchase |
2024-12-02 | 13G | Inozyme Pharma, Inc. INZY |
Affinity Healthcare Fund, LP | 3,972,318 6.180% |
3,972,318 (New Position) |
Filing History |
| 2024-11-13 4:06 pm Purchase |
2024-09-30 | 13G | NextCure, Inc. NXTC |
Affinity Healthcare Fund, LP | 2,302,598 8.220% |
629,759 (+37.65%) |
Filing History |
| 2024-08-14 4:05 pm Purchase |
2024-06-30 | 13G | Climb Bio, Inc. CLYM |
Affinity Healthcare Fund, LP | 1,813,193 2.700% |
143,193 (+8.57%) |
Filing History |
| 2024-06-27 4:47 pm Purchase |
2024-06-20 | 13G | NextCure, Inc. NXTC |
Affinity Healthcare Fund, LP | 1,672,839 5.980% |
1,672,839 (New Position) |
Filing History |
| 2024-05-07 6:01 pm Purchase |
2024-05-01 | 13G | Climb Bio, Inc. CLYM |
Affinity Healthcare Fund, LP | 1,670,000 6.020% |
1,670,000 (New Position) |
Filing History |
| 2024-02-13 4:55 pm Sale |
2023-12-31 | 13G | Vincerx Pharma, Inc. VINC |
Affinity Healthcare Fund, LP | 0 0.000% |
-74,639 (Position Closed) |
Filing History |
| 2024-02-13 4:48 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Affinity Healthcare Fund, LP | 653,409 1.810% |
653,409 (New Position) |
Filing History |
| 2024-02-13 4:45 pm Sale |
2023-12-31 | 13G | Context Therapeutics Inc. CNTX |
Affinity Healthcare Fund, LP | 328,817 2.060% |
-554,837 (-62.79%) |
Filing History |
| 2023-07-03 4:20 pm Purchase |
2023-06-22 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Affinity Healthcare Fund, LP | 299,080 9.230% |
299,080 (New Position) |
Filing History |
| 2023-02-13 4:11 pm Purchase |
2022-12-31 | 13G | Vincerx Pharma, Inc. VINC |
Affinity Healthcare Fund, LP | 74,639 7.040% |
17,870 (+31.48%) |
Filing History |
| 2022-05-09 5:11 pm Purchase |
2022-04-28 | 13G | Context Therapeutics Inc. CNTX |
Affinity Healthcare Fund, LP | 883,654 5.530% |
883,654 (New Position) |
Filing History |
| 2022-02-11 4:13 pm Purchase |
2021-12-31 | 13G | Vincerx Pharma, Inc. VINC |
Affinity Healthcare Fund, LP | 56,768 5.390% |
2,957 (+5.50%) |
Filing History |
| 2021-11-22 2:50 pm Purchase |
2021-11-10 | 13G | Vincerx Pharma, Inc. VINC |
Affinity Healthcare Fund, LP | 53,811 5.120% |
53,811 (New Position) |
Filing History |